Biomarker data suggest TNFi non-responders in PsA exhibit upregulation of IL-17F gene signatures after treatment failure. Supports IL-17A/F blockade rationale with bimekizumab in TNFi-experienced patients Abstract#OP0091 @RheumNow . #EULAR2025 https://t.co/CWR6ArDRRW

• https://x.com/synovialjoints/status/1932912825858429121/photo/1

SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks: •Early TNFi: 3.7 •Combo csDMARDs: 4.1 •Step-up csDMARDs: 4.7 Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2

• https://x.com/synovialjoints/status/1932915635928940957/photo/1

Precision immunotherapy in axial spondyloarthritis: TRBV9xCD3 bispecific antibodies selectively depleted autoreactive TRBV9+ T cells from HLA-B27+ AS patient samples while sparing over 95 percent of the T cell repertoire. TRBV9xCD3 bispecific antibodies selectively depleted https://t.co/8UXqEaDYnS

• https://x.com/synovialjoints/status/1932917464574406770/photo/1

In vitro, balinatunfib (TNFR1-selective inhibitor) preserved Treg expansion in CD4+ T cells co-cultured with IL-2 and memTNF (Treg 8.99 percent, p<0.0001), unlike adalimumab and etanercept which reduced Tregs by 27.5 to 41 percent. Confirms TNFR2 sparing with selective TNFR1 https://t.co/xaczz87Xrd

• https://x.com/synovialjoints/status/1932918407331979266/photo/1

VEGF-Grab (PB101/PB102), dual VEGF/PlGF decoy receptor, inhibited angiogenesis, RA-FLS invasion, and Th17 cell differentiation in RA and MS models. PB102 reduced IL-17 and GM-CSF co-expressing Th17 cells, suppressed pannus and joint destruction in CIA, and outperformed IFN-β in https://t.co/qhVRYT4RbK

• https://x.com/synovialjoints/status/1932920559576232224/photo/1

❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 @RheumNow #Strategy https://t.co/W8fuzSgxbJ

• https://x.com/Nellziade/status/1932833759679963620/photo/1

Ph 2 RCT Sonelokimab (IL-17A- & IL-17F-inhibiting Nanobody) 24wks 207 pts SON 120 MDA 51% vs. 45% ADA Subgroups: female 52%, weight ≥100kg 53%, ≥3% BSA 55% Composite ACR70/PASI100 SON 120 48% vs. 19% ADA No new safety signal Ph 3 on the way 2 doses SON 60 &120 #OP0096 https://t.co/w5QtpKbi1W

• https://x.com/AurelieRheumo/status/1932830229816283416/photo/1
• https://x.com/AurelieRheumo/status/1932830229816283416/photo/1
• https://x.com/AurelieRheumo/status/1932830229816283416/photo/1
• https://x.com/AurelieRheumo/status/1932830229816283416/photo/1

❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis? 🅰️ Yes 🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025 OP0089 @RheumNow #Strategy https://t.co/24e7wUV2FB

• https://x.com/Nellziade/status/1932827204171530655/photo/1

GI symptoms in axSpA -Cohort of 370 pts with axSpAfrom New Zealand -Elevated fecal calprotectin ➡️ positive correlation with GI symptoms and high disease activity -Bowel symptoms associated with reduced quality of life. -Use of TNFi improved bowel symptoms over time. https://t.co/wA37G3HWyi

• https://x.com/AdelaCastro222/status/1932822048901841257/photo/1
• https://x.com/AdelaCastro222/status/1932822048901841257/photo/1
• https://x.com/AdelaCastro222/status/1932822048901841257/photo/1

MONITOR PsA 200+ pts secondary care "real-life" cohort 65 treated w/ combi csDMARDs 48weeks outcome and 96 weeks 49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD ‼️reasons for discontinuation was AEs in 60% cases not inefficacy Caveat: analysis not adjusted for https://t.co/L8EczgZTpP

• https://x.com/AurelieRheumo/status/1932823234577125636/photo/1
• https://x.com/AurelieRheumo/status/1932823234577125636/photo/1
• https://x.com/AurelieRheumo/status/1932823234577125636/photo/1

Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant improvement on DAI measures as well. -Fully humanized IgG4 mab may last longer in system and possible less ADAs. Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt

• https://x.com/AdelaCastro222/status/1932824996671373641/photo/1
• https://x.com/AdelaCastro222/status/1932824996671373641/photo/1

First line TNFi in RA in 140+ pts vs Standard of Care At 5 yrs outcome OR drug free remission 2.2 But no longer significant at 10yrs OR sustained remission 10yrs 1.91 OR single bioDMARDs 10yrs 2.64 Less 1% D2T #Poster0027 #EULAR2025 @RheumNow https://t.co/sL2XCbxPbl

• https://x.com/AurelieRheumo/status/1932809205779738869/photo/1

Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior to ADA for ACR20 (RR 1.28), HAQ-DI, VAS, but no difference in adverse events (RR 0.96) or DAS28-CRP improvement https://t.co/5mVY2Qvdms https://t.co/czxnlYHEAl

• Frontiers | Comparative effectiveness and safety of tofacitinib vs. adalimumab …

Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16

• https://x.com/JihaRheum/status/1932813824723505162/photo/1

#OP0066 Danish registry study finds no increased risk of cancer recurrence with bDMARDs vs csDMARDs in RA patients with prior solid tumor in remission. IPTW-adjusted HR for any bDMARD: 0.92 (95% CI 0.38–2.21). 📉 TNFi, ,RTX also not associated with recurrence @RheumNow #EULAR2025